Eli Lilly and Company (NYSE:LLY) Stock Position Increased by LGT Fund Management Co Ltd.

LGT Fund Management Co Ltd. lifted its position in Eli Lilly and Company (NYSE:LLY) by 89.4% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 17,724 shares of the company’s stock after purchasing an additional 8,367 shares during the quarter. Eli Lilly and Company comprises 2.0% of LGT Fund Management Co Ltd.’s holdings, making the stock its 10th largest position. LGT Fund Management Co Ltd.’s holdings in Eli Lilly and Company were worth $16,047,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the company. Lynx Investment Advisory acquired a new stake in Eli Lilly and Company during the 2nd quarter worth about $32,000. LGT Financial Advisors LLC acquired a new stake in Eli Lilly and Company during the second quarter worth about $36,000. Morton Brown Family Wealth LLC raised its position in Eli Lilly and Company by 45.5% during the second quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock valued at $41,000 after acquiring an additional 15 shares in the last quarter. Core Wealth Advisors Inc. lifted its holdings in Eli Lilly and Company by 188.2% in the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after acquiring an additional 32 shares during the period. Finally, Activest Wealth Management purchased a new stake in Eli Lilly and Company in the 1st quarter worth approximately $39,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 194,978 shares of the company’s stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $885.91, for a total value of $172,732,959.98. Following the transaction, the insider now directly owns 97,583,810 shares in the company, valued at approximately $86,450,473,117.10. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold a total of 661,900 shares of company stock worth $604,721,602 over the last three months. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Up 0.6 %

LLY stock opened at $908.39 on Tuesday. Eli Lilly and Company has a one year low of $516.57 and a one year high of $972.53. The firm has a market cap of $863.36 billion, a PE ratio of 133.78, a PEG ratio of 2.73 and a beta of 0.42. The firm’s 50 day moving average price is $895.85 and its 200-day moving average price is $829.55. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. The company had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. On average, equities research analysts anticipate that Eli Lilly and Company will post 16.51 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 0.57%. The ex-dividend date of this dividend is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 76.58%.

Analysts Set New Price Targets

Several research firms have recently weighed in on LLY. BMO Capital Markets lifted their target price on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Jefferies Financial Group upped their price objective on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a research report on Monday, June 24th. Berenberg Bank raised their target price on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. JPMorgan Chase & Co. lifted their price target on shares of Eli Lilly and Company from $900.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Thursday, July 11th. Finally, Barclays boosted their target price on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 10th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $961.76.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.